Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Sitagliptin (Januvia®) 25 and 50 mg tablets. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2912. 2012 Authors' conclusions Sitagliptin (Januvia®) 25 and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl = 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis. Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Pyrazines; Triazoles Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000877 Date abstract record published 26/11/2012 |